TNXP · Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals announced Q1 2026 results highlighting the early commercialization success of TONMYA, the first new fibromyalgia treatment in 15 years approved in August 2025 and launched November 17, 2025. Net product revenue reached $6.9 million, up from $2.4 million year-over-year, with TONMYA contributing $3.7 million in its first full quarter post-launch. This reflects robust adoption: 2,145 unique healthcare providers wrote prescriptions, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled, including bridge prescriptions via the specialty pharmacy channel while awaiting coverage. Legacy products Zembrace SymTouch and Tosymra added $3.2 million. Cost of sales rose to $1.6 million from $0.9 million, aligned with higher volumes. CEO Seth Lederman emphasized TONMYA's non-opioid profile for bedtime use and growth in prescriptions, new writers, refills, and access, bolstered by a May 2026 GPO agreement covering 35 million commercial lives and Medicaid coverage in 38 states for 55 million lives. Operational cash burn increased to $42.3 million from $16.6 million year-over-year, reflecting sales force expansion to 100 reps and market access investments. Cash stood at $185.5 million as of March 31, 2026, supplemented by $22.6 million from ATM offerings, sufficient into early Q2 2027. Pipeline progress includes Phase 2 initiations for TNX-102 SL in MDD mid-2026, TNX-4800 Lyme prevention field study H1 2027 pending FDA, and others in CNS, infectious disease, and immunology, positioning Tonix for multiple catalysts.